secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001104659-23-033086
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome reports Q4 2022 net loss $7.8M; announces AbbVie collaboration with $30M upfront
--------------------------------------------------------------------------------

- Net loss of $7.8M ($0.64 per share) for Q4 2022; full-year net loss $36.9M ($3.09 per share).
- Cash and equivalents $20.3M as of Dec 31, 2022.
- Entered strategic collaboration with AbbVie for up to 10 novel antibody-target pairs; $30M upfront plus up to $70M platform milestones.
- Per target: up to $120M in development/commercial milestones, $150M in sales milestones, plus tiered royalties.
- Seeking partner for COVID-19 antibody cocktail IMM-BCP-01 after Phase 1b cohort completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923033086/0001104659-23-033086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923033086/tm239583d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-033086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer